Contemporary OB/GYN's top headlines from April 2026

As we get set to move into the month of May 2026, there were several key headlines that Contemporary OB/GYN highlighted, from our several expert interviews, to new data, FDA clearances, and more.

In the list below, take a look back at our most-viewed stories from the month of April 2026, and click each headline for the full article or video, as it was reported at the time of publishing.

Contemporary OB/GYN is kicking off the month of May with several articles, abstract and poster coverage, and expert commentary from the 2026 American College of Obstetricians & Gynecologists’ 75th Annual Clinical & Scientific Meeting, being held in Washington, D.C., from May 1-3, 2026.

Click here to stay up to date with our latest coverage as it occurs from the 2026 ACOG Meeting, and consider subscribing to our free e-newsletter for direct meeting news, delivered right to your inbox. Click here to register.

Contemporary OB/GYN’s top headlines from April 2026

Wearable device designed for perimenopause launches

On April 2, 2026, Peri, a women’s health and data company, launched the first wearable device specifically engineered to monitor perimenopause, according to a press release from the company. The system utilizes continuous biometric tracking to provide an objective assessment of physiological changes over time, offering actionable insights for symptom management and clinical care.

ACOG updates guidance for evaluating postmenopausal bleeding

• ACOG now recommends both transvaginal ultrasound and endometrial biopsy for most patients with postmenopausal bleeding.
• About 90% of endometrial cancer cases present with postmenopausal bleeding.
• Ultrasound alone may miss 5% to 12% of cancers at initial evaluation.

AMA, ACOG announce restructuring of maternity care coding for 2027

• The restructure replaces the single "global" code with 4 specific phases of care: antepartum, labor management, delivery, and postpartum.
• The changes are designed to support tailored prenatal care, including modified visit schedules, home monitoring, and telehealth.
• Most patients will not see cost increases for prenatal visits due to Affordable Care Act protections for preventive services.

FDA clears Control-IQ+AID technology for use in pregnancy complicated by type 1 diabetes

On April 27, 2026, Tandem Diabetes Care announced the expanded FDA clearance of the Control-IQ+ automated insulin delivery (AID) technology for use in pregnancies complicated by type 1 diabetes mellitus. This regulatory clearance covers both the t:slim X2 and Tandem Mobi insulin delivery systems, making them the first and only commercially available AID systems in the United States cleared for use during pregnancy

FDA says "study may proceed" for Vistagen's refisolone nasal spray for vasomotor symptoms

Vistagen’s refisolone nasal spray, in development to treat moderate-to-severe vasomotor symptoms because of menopause, got a green light for continued phase 2 clinical development after receipt of a “Study May Proceed” letter from the FDA.

The continuation comes after refisolone demonstrated improvements vs placebo in frequency and severity of daily menopausal hot flashes.